1Koenen F, De Clercq K, Lefebvre J, et al. Reproductive failure in sows following experimental infection with a Belgian EMCV isolate [J]. Vet Microbiol, 1994, 39: 111-116.
3Sin J I, Sung J H, Suh Y S, et al. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene [J]. Vaccine, 1997, 15: 1827-1833.
4Emerson C L, Wagner J L. Antibody responses to two encephalomyocarditis virus vaccines in rhesus macaques (Macaca mulatta) [J]. J Med Primatol, 1996, 25 (1): 42-45.
5Pamela Hunter, Swanepoel S P, Esterhuysen J J, et al. The efficacy of an experimental oil adjuvanted encephalomyocarditis vaccine in elephants, mice and pigs [J]. Vaccine, 1998, 16 (1): 55-61.
6Gomez L, Trujillo N, Lorenzo, et al. Production, development and field evaluation of the first inactivated vaccine against viral encephalomyocar-ditis [J]. Source Revista Cubana de Ciencias Veterinarias, 1995, 24(2): 9-15.
7McLelland D J, Kirkland P D, Rose K A, et al. Serologic responses of Barbary sheep, Indian antelope, wallaroos, and chimpanzees to an inactivated encephalomyocarditis virus vaccine [J]. J Zoo Wildl Med, 2005, 36(1): 69-73.
8Bogaerts W J C, Durville-van der Oord B J. Immunization of mice with live attenuated encephalomyocarditis virus: local immunity and survival [J]. Infect Immunity, 1973, 8(4): 528- 533.
9Suh Y S, Ha S J, Lee C H, et al. Enhancement of VP1-specific immune responses and protection against EMCV-K challenge by co-delivery of IL-12 DNA with VP1 DNA vaccine [J]. Vaccine, 2001, 19: 1891-1898.
10Jun H S, Yoon S W, Kang Y, et al. Cloning and expression of the VP1 major capsid protein of diabetogenic encephalomyocarditis (EMC) virus and prevention of EMC virus-induced diabetes by immunization with the recombinant VP1 protein [J]. J Gen Virol, 1995, 76: 2557-2566.
3Bae Y S, Eun H M, Yoon J W. Genomic differences between the diabetogenie and non diabetogenic variants of encephalomyocarditis virus [J]. Virology, 1989, 170 (1) : 282-287.
4Donnelly, G ani D, Flin T M. The cleavage activity of aphthovirus and eardiovirus 2A proteins [J]. J Gen Virol, 1997, 78 (1) : 13-21.
5Groppo R,Brown B A, Palmenberg A C. Mutational analysis of the EMCV 2A protein identifies a nuclear localization signal and an eIF4E binding site[J].Virology,2011, 410:257-267.
6Pfister T, Jones K W, Wimmer E. A cysteine-rich motif in polio-virus protein 2C(ATPase) is involved in RNA replication and binds zinc in vitro[J]. Virol, 2000, 74(1) : 334-343.
7Allaire M, Chernaia M M, Malcolm B A, et al. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin- like serine proteinases[J].Nature, 1994, 369(6475) : 72-76.
8Borghese F, Michiels T. The leader protein of cardioviruses inhibits stress granule assembly[J]. Virology,2011, 85(15) : 9614-9622.
9Obertson M E, Seamons R A, Belsham G L. A selection system for functional internal ribosome entry site (IRES) elements: analysis of the requirement for a conserved GNRA tetraloop in the encephalomyoearditis virus IRES [J]. RNA, 1999, 5(9) :1167-79.
10Zhao W D, Wimmer E. Genetic analysis of a poliovirus/hepa titis C virus chimera: new structure for domain II of the in ternal ribosomal entry site of hepatitis C virus[J]. Virology 2001, 75 (8):3719-3730.
